Literature DB >> 28912274

Structure, mechanism, and regulation of polycomb-repressive complex 2.

Lindsay E Moritz1, Raymond C Trievel2.   

Abstract

Polycomb repressive complex 2 (PRC2) methylates lysine 27 in histone H3, a modification associated with epigenetic gene silencing. This complex plays a fundamental role in regulating cellular differentiation and development, and PRC2 overexpression and mutations have been implicated in numerous cancers. In this Minireview, we examine recent studies elucidating the first crystal structures of the PRC2 core complex, yielding seminal insights into its catalytic mechanism, substrate specificity, allosteric regulation, and inhibition by a class of small molecules that are currently undergoing cancer clinical trials. We conclude by exploring unresolved questions and future directions for inquiry regarding PRC2 structure and function.
© 2018 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Enhancer of Zeste 2 (EZH2); Polycomb repressive complex 2 (PRC2); SET domain; cancer; chromatin; crystal structure; epigenetics; gene silencing; histone methylation; lysine methyltransferase

Mesh:

Substances:

Year:  2017        PMID: 28912274      PMCID: PMC6130931          DOI: 10.1074/jbc.R117.800367

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  82 in total

1.  Structural basis for specific binding of Polycomb chromodomain to histone H3 methylated at Lys 27.

Authors:  Jinrong Min; Yi Zhang; Rui-Ming Xu
Journal:  Genes Dev       Date:  2003-08-01       Impact factor: 11.361

2.  Substrate preferences of the EZH2 histone methyltransferase complex.

Authors:  Cyrus Martin; Ru Cao; Yi Zhang
Journal:  J Biol Chem       Date:  2006-01-23       Impact factor: 5.157

3.  H3K36 methylation antagonizes PRC2-mediated H3K27 methylation.

Authors:  Wen Yuan; Mo Xu; Chang Huang; Nan Liu; She Chen; Bing Zhu
Journal:  J Biol Chem       Date:  2011-01-14       Impact factor: 5.157

4.  A Polycomb group protein complex with sequence-specific DNA-binding and selective methyl-lysine-binding activities.

Authors:  Tetyana Klymenko; Bernadett Papp; Wolfgang Fischle; Thomas Köcher; Malgorzata Schelder; Cornelia Fritsch; Brigitte Wild; Matthias Wilm; Jürg Müller
Journal:  Genes Dev       Date:  2006-04-17       Impact factor: 11.361

5.  The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat.

Authors:  Kevin W Kuntz; John E Campbell; Heike Keilhack; Roy M Pollock; Sarah K Knutson; Margaret Porter-Scott; Victoria M Richon; Chris J Sneeringer; Tim J Wigle; Christina J Allain; Christina R Majer; Mikel P Moyer; Robert A Copeland; Richard Chesworth
Journal:  J Med Chem       Date:  2016-01-27       Impact factor: 7.446

Review 6.  Targeting EZH2 in cancer.

Authors:  Kimberly H Kim; Charles W M Roberts
Journal:  Nat Med       Date:  2016-02       Impact factor: 53.440

7.  Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.

Authors:  Satoshi Kawano; Alexandra R Grassian; Masumi Tsuda; Sarah K Knutson; Natalie M Warholic; Galina Kuznetsov; Shanqin Xu; Yonghong Xiao; Roy M Pollock; Jesse S Smith; Kevin K Kuntz; Scott Ribich; Yukinori Minoshima; Junji Matsui; Robert A Copeland; Shinya Tanaka; Heike Keilhack
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

8.  Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas.

Authors:  Rishi G Vaswani; Victor S Gehling; Les A Dakin; Andrew S Cook; Christopher G Nasveschuk; Martin Duplessis; Priyadarshini Iyer; Srividya Balasubramanian; Feng Zhao; Andrew C Good; Robert Campbell; Christina Lee; Nico Cantone; Richard T Cummings; Emmanuel Normant; Steven F Bellon; Brian K Albrecht; Jean-Christophe Harmange; Patrick Trojer; James E Audia; Ying Zhang; Neil Justin; Shuyang Chen; Jon R Wilson; Steven J Gamblin
Journal:  J Med Chem       Date:  2016-10-28       Impact factor: 7.446

9.  AEBP2 as a potential targeting protein for Polycomb Repression Complex PRC2.

Authors:  Hana Kim; Keunsoo Kang; Joomyeong Kim
Journal:  Nucleic Acids Res       Date:  2009-03-17       Impact factor: 16.971

10.  PRC2 binds active promoters and contacts nascent RNAs in embryonic stem cells.

Authors:  Syuzo Kaneko; Jinsook Son; Steven S Shen; Danny Reinberg; Roberto Bonasio
Journal:  Nat Struct Mol Biol       Date:  2013-10-20       Impact factor: 15.369

View more
  31 in total

Review 1.  Off to a Bad Start: Cancer Initiation by Pluripotency Regulator PRDM14.

Authors:  Lauren J Tracey; Monica J Justice
Journal:  Trends Genet       Date:  2019-05-23       Impact factor: 11.639

Review 2.  Milestones in transcription and chromatin published in the Journal of Biological Chemistry.

Authors:  Joel M Gottesfeld
Journal:  J Biol Chem       Date:  2019-02-01       Impact factor: 5.157

Review 3.  Polycomb repressive 2 complex-Molecular mechanisms of function.

Authors:  Valentina L Kouznetsova; Alex Tchekanov; Xiaoming Li; Xiaowen Yan; Igor F Tsigelny
Journal:  Protein Sci       Date:  2019-06-10       Impact factor: 6.725

Review 4.  Introduction to the Thematic Minireview Series: Chromatin and transcription.

Authors:  Joel M Gottesfeld; Michael F Carey
Journal:  J Biol Chem       Date:  2018-08-01       Impact factor: 5.157

Review 5.  Targeting epigenetic protein-protein interactions with small-molecule inhibitors.

Authors:  Brian M Linhares; Jolanta Grembecka; Tomasz Cierpicki
Journal:  Future Med Chem       Date:  2020-06-19       Impact factor: 3.808

6.  Inhibition of polycomb repressor complex 2 ameliorates neointimal hyperplasia by suppressing trimethylation of H3K27 in vascular smooth muscle cells.

Authors:  Jing Liang; Qi Li; Wenbin Cai; Xuejiao Zhang; Bing Yang; Xin Li; Shuai Jiang; Shanshan Tian; Kai Zhang; Hao Song; Ding Ai; Xu Zhang; Chunjiong Wang; Yi Zhu
Journal:  Br J Pharmacol       Date:  2019-07-19       Impact factor: 8.739

Review 7.  Long non-coding RNA MIR4435-2HG: a key molecule in progression of cancer and non-cancerous disorders.

Authors:  Majid Ghasemian; Masoumeh Rajabibazl; Unes Sahebi; Samira Sadeghi; Reza Maleki; Veys Hashemnia; Reza Mirfakhraie
Journal:  Cancer Cell Int       Date:  2022-06-17       Impact factor: 6.429

Review 8.  Domain cross-talk in regulation of histone modifications: Molecular mechanisms and targeting opportunities.

Authors:  James E Longbotham; Meng Yao Zhang; Danica Galonić Fujimori
Journal:  Curr Opin Chem Biol       Date:  2020-08-03       Impact factor: 8.822

9.  Targeted reprogramming of H3K27me3 resets epigenetic memory in plant paternal chromatin.

Authors:  Michael Borg; Yannick Jacob; Daichi Susaki; Chantal LeBlanc; Daniel Buendía; Elin Axelsson; Tomokazu Kawashima; Philipp Voigt; Leonor Boavida; Jörg Becker; Tetsuya Higashiyama; Robert Martienssen; Frédéric Berger
Journal:  Nat Cell Biol       Date:  2020-05-11       Impact factor: 28.824

10.  Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer.

Authors:  Xin Li; Lajos Gera; Shumin Zhang; Yanhua Chen; Lei Lou; Lauren Marie Wilson; Zhong-Ru Xie; Giuseppe Sautto; Degang Liu; Alira Danaher; Kenza Mamouni; Yang Yang; Yuhong Du; Haian Fu; Omer Kucuk; Adeboye O Osunkoya; Jia Zhou; Daqing Wu
Journal:  Theranostics       Date:  2021-05-08       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.